ARTICLE | Product Development
Rivus reports weight loss POC with metabolic accelerator
Mechanism leads to significant weight loss, fat reduction in Phase IIa
February 10, 2022 2:41 AM UTC
The first clinical POC data from Rivus points to what could be a differentiated weight loss mechanism that might have utility across a range of metabolic disorders.
The Charlottesville, Va., biotech announced on Wednesday that a Phase IIa trial of HU6 met the primary endpoint of a significant reduction in liver fat as measured by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), as well as secondary endpoints such as body weight reduction and fat reduction measured by abdominal MRI...